SCHOTT Pharma AG & Co KgaA

Chart & Performance

D1W1MN

P/E

24.12

P/S

4.08

EPS

1.01

Div Yield, %

0.52%

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

957m

+6.51%

Net income

150m

-1.42%

CFO

225m

+24.04%

Dividend

Mar 15, 20240.15 EUR/sh

Earnings

Feb 27, 2025

Profile

SCHOTT Pharma AG & Co. KGaA develops, produces, and sells drug containment solutions and delivery systems for injectable drugs to the pharmaceutical and biotechnology industries worldwide. The company offers polymer and glass syringes, ampoules, vials, and cartridges. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container. The company's cartridge products comprise cartriQ, a pharmaceutical glass cartridge for peptide and protein-based injectables; cartriQ Large Volume, a pharmaceutical glass cartridge for large-volume injectables; Cartridges Double Chamber, a pharmaceutical glass cartridge for lyophilized drugs; Cartridges Break Resistant, a pharmaceutical glass cartridge; and TopLine and StandardLine cartridges. Its vial products include adaptiQ, a pharmaceutical glass vial for injectables; EVERIC pure, a pharmaceutical glass vial for unmatched drug stability; EVERIC care, a pharmaceutical glass vial for a pH range; EVERIC strong & smooth, a pharmaceutical glass vial for the filling line performance; SCHOTT Type I plus, a pharmaceutical glass vial for drug formulations; SCHOTT TopLyo, a pharmaceutical glass vial to avoid fogging for lyophilized drugs; and TopLine and StandardLine vials. Its ampoule products comprise Ampoules easyOPC, a pharmaceutical glass ampoule for ampoule opening; Ampoules Anti-Counterfeiting, a pharmaceutical glass ampoule for protection against drug counterfeiting; and StandardLine ampoules. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

URL

https://www.schott-pharma.com/

IPO date

Sep 28, 2023

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2024‑09	2023‑09	2022‑09	2021‑09	2020‑09
Income
Revenues	957,091 6.51%	898,602 9.43%	821,144 26.59%
Cost of revenue	783,211	731,024	658,454
Unusual Expense (Income)
NOPBT	173,880	167,578	162,690
NOPBT Margin	18.17%	18.65%	19.81%
Operating Taxes	33,626	33,868	32,441
Tax Rate	19.34%	20.21%	19.94%
NOPAT	140,254	133,710	130,249
Net income	149,685 -1.42%	151,842 21.11%	125,379 24.44%
Dividends	(22,592)	(18,878)	(11,456)
Dividend yield	0.49%	0.40%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	4,928	3,138	3,375
Long-term debt	166,676	141,524	146,241
Deferred revenue	78,611	66,139	39,949
Other long-term liabilities	33,410	28,349	20,441
Net debt	63,360	39,700	41,000
Cash flow
Cash from operating activities	225,326	181,652	182,123
CAPEX	(145,075)	(175,524)	(152,688)
Cash from investing activities	(145,929)	(171,411)	(142,136)
Cash from financing activities	(78,156)	(11,395)	(42,382)
FCF	2,367	100,094	(225,931)
Balance
Cash	26,431	25,889	30,284
Long term investments	81,813	79,073	78,332
Excess cash	60,389	60,032	67,559
Stockholders' equity	152,478	189,316	1,390,951
Invested Capital	929,703	784,337	761,357
ROIC	16.37%	17.30%	22.33%
ROCE	17.19%	18.96%	18.88%
EV
Common stock shares outstanding	150,615	150,615	150,615
Price	30.66 -3.10%	31.64
Market cap	4,617,856 -3.10%	4,765,459
EV	4,683,079	4,806,907
EBITDA	238,858	219,426	218,047
EV/EBITDA	19.61	21.91
Interest	13,487	7,254	2,686
Interest/NOPBT	7.76%	4.33%	1.65%